We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Global Coagulation Testing Driven by Increasing Blood Disorders and Surgical Interventions

By LabMedica International staff writers
Posted on 15 Aug 2024

As the global population ages, there is an increasing demand for coagulation testing, particularly among the elderly who face a higher risk of thrombotic events and coagulation disorders. More...

Clotting factors crucial for coagulation testing include fibrinogen, prothrombin, thromboplastin, calcium, and antihemophilic factors, with prothrombin being a key plasma protein synthesized by the liver, essential for coagulation. These tests are critical in diagnosing diseases such as bleeding disorders or clotting disorders, aimed at identifying deficiencies in clotting factors and detecting the progression of liver diseases or a vitamin K deficiency. Rapid economic development and improving healthcare infrastructure in emerging markets are increasing access to coagulation testing, driving market growth, and serving previously underserved populations. The global coagulation testing market is projected to grow at a CAGR of 6.0% from 2024 to 2034, reaching USD 6.5 billion by 2034. The rise in surgical interventions, including complex procedures like cardiac surgeries and organ transplants, is boosting the need for coagulation testing to monitor patients' clotting status and minimize bleeding risks.

These are the latest findings by Transparency Market Research (Wilmington, DE, USA), a market research firm.

The coagulation testing market is experiencing significant growth, driven by the rising incidence of liver diseases, cardiovascular conditions, and blood disorders. These tests are fundamentally used for diagnosing and monitoring unexplained bleeding, managing anticoagulant therapy, and assessing liver disease progression. Modern developments include innovative point-of-care (POC) solutions that quickly assess a patient’s coagulation status and are compatible with all types of anticoagulants, including direct oral anticoagulants, enhancing patient outcomes and simplifying clinical procedures.

These advancements have increased the importance of POC coagulation tests for the early detection of bleeding disorders and close monitoring of anticoagulant therapy effects. Manufacturers are developing advanced POC devices based on these needs. The growing preference for home-based healthcare is spurring the development of portable, user-friendly coagulation testing devices that allow patients to easily monitor their clotting status, thereby broadening market reach. Additionally, the increasing focus on personalized medicine is pushing the demand for coagulation tests that are tailored to individual patient needs, enhancing treatment precision and optimizing therapeutic outcomes.

Based on product type, the consumables segment is leading the coagulation testing market, driven by ongoing demand for reagents, kits, and other testing consumables. Based on test type, the PT segment is dominating the coagulation testing market, providing essential insights into the extrinsic clotting pathway and overall coagulation status. By end user, the hospitals and clinics segment is leading the coagulation testing market, offering extensive diagnostic services and managing diverse patient conditions.

Geographically, the North American coagulation testing market, especially the United States, is being driven by its sophisticated healthcare systems and a high prevalence of chronic conditions that require frequent coagulation tests. The region is benefitting from well-established diagnostic labs and hospitals that provide a comprehensive range of testing services and products, with strict regulatory standards ensuring the quality and reliability of these tools. Europe has a mature coagulation testing market, led by nations such as Germany, France, and the United Kingdom, characterized by strong healthcare infrastructure and extensive R&D activities. Technological advancements in testing techniques and a focus on patient safety are boosting the market growth in Europe. Collaborations between academic sectors and industry are driving innovations in coagulation testing. In Asia Pacific, economic growth and increasing healthcare investments are propelling the coagulation testing market, with countries like China, India, and Japan experiencing rising demand for coagulation testing due to rising chronic disease rates and improved healthcare accessibility.

Related Links:
Transparency Market Research


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Integrated Biochemical & Immunological System
Biolumi CX8
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.